

# Tae Min Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/548228/publications.pdf>

Version: 2024-02-01

261  
papers

11,185  
citations

50276

46  
h-index

38395

95  
g-index

267  
all docs

267  
docs citations

267  
times ranked

15901  
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study). <i>Cancer Research and Treatment</i> , 2022, 54, 396-405.	3.0	2
2	Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. <i>Journal of Thoracic Oncology</i> , 2022, 17, 103-115.	1.1	89
3	Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. <i>Blood Advances</i> , 2022, 6, 533-543.	5.2	77
4	Primary Prophylaxis for <i>Pneumocystis jirovecii</i> Pneumonia in Patients Receiving Rituximab. <i>Chest</i> , 2022, 161, 1201-1210.	0.8	23
5	Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors. <i>Laboratory Investigation</i> , 2022, 102, 160-171.	3.7	21
6	Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open-label phase 2 study. <i>Cancer Medicine</i> , 2022, 11, 371-379.	2.8	9
7	Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. <i>Lancet Oncology</i> , The, 2022, 23, 53-64.	10.7	165
8	Risk Stratification to Define the Role of Radiotherapy for Benign and Atypical Meningioma: A Recursive Partitioning Analysis. <i>Neurosurgery</i> , 2022, 90, 619-626.	1.1	4
9	Added Value of Contrast Leakage Information over the CBV Value of DSC Perfusion MRI to Differentiate between Pseudoprogression and True Progression after Concurrent Chemoradiotherapy in Glioblastoma Patients. <i>Investigative Magnetic Resonance Imaging</i> , 2022, 26, 10.	0.4	1
10	<i>ALK</i> Translocation in <i>ALK</i> -Positive Mesenchymal Tumors: Diagnostic and Therapeutic Insights. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 1460-1470.	2.5	3
11	Abstract 5477: Compound A, a fourth-generation allosteric inhibitor, a potent and highly selective EGFR with L858R activating and C797S resistance mutations for the treatment of NSCLC. <i>Cancer Research</i> , 2022, 82, 5477-5477.	0.9	0
12	Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9039-9039.	1.6	9
13	A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with <i>EGFR</i> -mutant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9142-TPS9142.	1.6	5
14	A phase 1/2 study of BLU-945 in patients with common activating <i>EGFR</i> -mutant non-small cell lung cancer (NSCLC): SYMPHONY trial in progress.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9156-TPS9156.	1.6	6
15	Radiological assessment schedule for high-grade glioma patients during the surveillance period using parametric modeling. <i>Neuro-Oncology</i> , 2021, 23, 837-847.	1.2	9
16	Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1605-1617.	4.2	8
17	Long-Term Outcomes and Sequelae Analysis of Intracranial Germinoma: Need to Reduce the Extended-Field Radiotherapy Volume and Dose to Minimize Late Sequelae. <i>Cancer Research and Treatment</i> , 2021, 53, 983-990.	3.0	8
18	Radiological assessment schedule for 1p/19q-codeleted gliomas during the surveillance period using parametric modeling. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab069.	0.7	0

#	ARTICLE	IF	CITATIONS
19	Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas. Korean Journal of Radiology, 2021, 22, 233.	3.4	6
20	Clinical pattern of failure after a durable response to immune checkpoint inhibitors in non-small cell lung cancer patients. Scientific Reports, 2021, 11, 2514.	3.3	17
21	Prediction of Prognosis in Glioblastoma Using Radiomics Features of Dynamic Contrast-Enhanced MRI. Korean Journal of Radiology, 2021, 22, 1514.	3.4	21
22	Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues. Cancer Immunology, Immunotherapy, 2021, 70, 1755-1769.	4.2	4
23	Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 699-711.	2.8	12
24	Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. Journal of Hematology and Oncology, 2021, 14, 25.	17.0	41
25	Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment. Cancer Research and Treatment, 2021, 53, 1195-1203.	3.0	4
26	Clinical and Genomic Characteristics of Adult Diffuse Midline Glioma. Cancer Research and Treatment, 2021, 53, 389-398.	3.0	14
27	A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. Haematologica, 2021, 106, 2277-2280.	3.5	9
28	Differentiation between glioblastoma and primary CNS lymphoma: application of DCE-MRI parameters based on arterial input function obtained from DSC-MRI. European Radiology, 2021, 31, 9098-9109.	4.5	12
29	A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 3113-3113.	1.6	3
30	Interim analysis of first-in-human phase 1 study to assess safety and efficacy of YBL-006, an anti-PD-1 antibody in advanced solid tumor with exploratory biomarker analysis of tumor mutational burden and artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes.. Journal of Clinical Oncology, 2021, 39, e14552-e14552.	1.6	0
31	Radiomics-based neural network predicts recurrence patterns in glioblastoma using dynamic susceptibility contrast-enhanced MRI. Scientific Reports, 2021, 11, 9974.	3.3	22
32	Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.. Journal of Clinical Oncology, 2021, 39, 9515-9515.	1.6	22
33	Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.. Journal of Clinical Oncology, 2021, 39, 9014-9014.	1.6	23
34	A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion.. Journal of Clinical Oncology, 2021, 39, 3007-3007.	1.6	11
35	Effects of percutaneous injection laryngoplasty on voice and swallowing problems in <scp>cancer-related</scp> unilateral vocal cord paralysis. Laryngoscope Investigative Otolaryngology, 2021, 6, 800-806.	1.5	2
36	A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. Investigational New Drugs, 2021, 39, 1624-1632.	2.6	0

#	ARTICLE	IF	CITATIONS
37	Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG)., 2021, , .		5
38	Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR T790M-Mutant NSCLC. Journal of Thoracic Oncology, 2021, 16, 1859-1871.	1.1	16
39	Cancer Patientsâ€™ Willingness to Take COVID-19 Vaccination: A Nationwide Multicenter Survey in Korea. Cancers, 2021, 13, 3883.	3.7	48
40	Tumor <sc>LAG</sc> and <sc>NYâ€SO</sc> expression predict durable clinical benefits of immune checkpoint inhibitors in advanced nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 619-630.	1.9	8
41	Role of concurrent chemoradiation on locally advanced unresectable adenoid cystic carcinoma. Korean Journal of Internal Medicine, 2021, 36, 175-181.	1.7	13
42	Treatment with pembrolizumab in programmed death ligand 1â€positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTEâ€028 trial. Cancer, 2021, 127, 1620-1629.	4.1	56
43	Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertionâ€Positive Metastatic Nonâ€Small Cell Lung Cancer. JAMA Oncology, 2021, 7, e214761.	7.1	160
44	Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Scientific Reports, 2021, 11, 19712.	3.3	54
45	Temporal evolution of PD-L1 expression in patients with non-small cell lung cancer. Korean Journal of Internal Medicine, 2021, 36, 975-984.	1.7	5
46	A Phase 1 Dose Escalation Study of Dual PI3K and DNA PK Inhibitor, BR101801 in Adult Patients with Advanced Hematologic Malignancies. Blood, 2021, 138, 3562-3562.	1.4	1
47	Use of Positron Emission Tomography in Patients with Classical Hodgkin Lymphoma Outside of Europe and North America: Results from the International, Multi-Center, Retrospective B-Holistic Study. Blood, 2021, 138, 1397-1397.	1.4	0
48	Clinical Application of Next-Generation Sequencingâ€Based Panel to <i>BRAF</i> Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies. Molecular Cancer Therapeutics, 2020, 19, 937-944.	4.1	14
49	Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2020, 38, 155-165.	1.6	488
50	Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors. Clinical Infectious Diseases, 2020, 71, 422-425.	5.8	32
51	Osimertinib in Patients With Epidermal Growth Factor Receptor Mutationâ€Positive Nonâ€Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. Journal of Clinical Oncology, 2020, 38, 538-547.	1.6	221
52	Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells. Cancer Letters, 2020, 495, 135-144.	7.2	8
53	Phase <sc>II</sc> study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: <sc>KCSGâ€LU16</sc>. Thoracic Cancer, 2020, 11, 3482-3489.	1.9	16
54	Genomic, transcriptomic, and viral integration profiles associated with recurrent/metastatic progression in highâ€risk human papillomavirus cervical carcinomas. Cancer Medicine, 2020, 9, 8243-8257.	2.8	4

#	ARTICLE	IF	CITATIONS
55	Capmatinib in <i>MET</i> Exon 14 Mutated or <i>MET</i> -Amplified Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 944-957.	27.0	542
56	Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 2931-2938.	1.3	13
57	Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma. <i>Theranostics</i> , 2020, 10, 10838-10848.	10.0	39
58	Hydroa vacciniforme-like lymphoproliferative disorder in Korea. <i>Scientific Reports</i> , 2020, 10, 19294.	3.3	4
59	Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. <i>European Journal of Cancer</i> , 2020, 135, 31-38.	2.8	11
60	Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 131-142.	2.8	14
61	Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. <i>Investigational New Drugs</i> , 2020, 38, 1472-1482.	2.6	8
62	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- $\beta$ 2 and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1210-1222.	1.1	119
63	Prognostication of anaplastic astrocytoma patients: application of contrast leakage information of dynamic susceptibility contrast-enhanced MRI and dynamic contrast-enhanced MRI. <i>European Radiology</i> , 2020, 30, 2171-2181.	4.5	7
64	Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value. <i>American Journal of Neuroradiology</i> , 2020, 41, 49-56.	2.4	11
65	ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 13-14.	1.4	18
66	Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 37-38.	1.4	37
67	A Phase 2 Study of Oronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 28-29.	1.4	9
68	Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension. <i>Blood</i> , 2020, 136, 17-19.	1.4	17
69	Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9505-9505.	1.6	24
70	Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9558-9558.	1.6	7
71	Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9593-9593.	1.6	12
72	Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma. <i>Radiation Oncology Journal</i> , 2020, 38, 35-43.	1.5	15

#	ARTICLE	IF	CITATIONS
73	Altered expression of fucosylation pathway genes is associated with poor prognosis and tumor metastasis in non-small cell lung cancer. <i>International Journal of Oncology</i> , 2020, 56, 559-567.	3.3	16
74	A pilot study of levetiracetam as a sensitizer of temozolomide for newly diagnosed glioblastoma: A prospective, open-label, phase II study (KBTS-1601 study).. <i>Journal of Clinical Oncology</i> , 2020, 38, 2560-2560.	1.6	1
75	A phase III, open-label, randomized study of atezolizumab in combination with carboplatin + paclitaxel + bevacizumab compared with pemetrexed + cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9636-TPS9636.	1.6	2
76	An open-label, multicenter, phase II study of ceritinib in patients with advanced ALK+ non-lung solid tumors and hematological malignancies (ASCEND-10).. <i>Journal of Clinical Oncology</i> , 2020, 38, 3520-3520.	1.6	1
77	GCT-02. THE LONG-TERM OUTCOMES AND SEQUELAE ANALYSIS OF INTRACRANIAL GERMINOMA FROM 187 PATIENTS IN THE SINGLE INSTITUTE: NECESSITY FOR THE ADAPTATION OF RADIOTHERAPY DOSE AND VOLUME. <i>Neuro-Oncology</i> , 2020, 22, iii328-iii329.	1.2	0
78	Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study). <i>Cancer Research and Treatment</i> , 2020, 52, 505-515.	3.0	9
79	288â€¦A phase 1 study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. , 2020, , .		0
80	Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 32-34.	1.4	0
81	Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1556-1566.	1.1	28
82	Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy. <i>Thrombosis Research</i> , 2019, 183, 131-135.	1.7	12
83	Histologicallyâ€¦diagnosed psoriasiform dermatitis induced by nivolumab successfully controlled by etanercept: A case report. <i>Journal of Dermatology</i> , 2019, 46, e464-e466.	1.2	4
84	The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinaseâ€¦positive non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 2117-2123.	1.9	9
85	A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer. <i>Lung Cancer</i> , 2019, 136, 122-128.	2.0	38
86	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. <i>Lancet Oncology</i> , The, 2019, 20, 1083-1097.	10.7	611
87	Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma. <i>Cell</i> , 2019, 177, 1842-1857.e21.	28.9	153
88	First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis. <i>Clinical Lung Cancer</i> , 2019, 20, 331-338.e4.	2.6	47
89	NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors. <i>Cytotherapy</i> , 2019, 21, 603-611.	0.7	15
90	Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e442-e451.	2.6	15

#	ARTICLE	IF	CITATIONS
91	Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 143, 321-328.	2.9	34
92	Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study. <i>Oncologist</i> , 2019, 24, e740-e748.	3.7	38
93	Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis. <i>ESMO Open</i> , 2019, 4, e000575.	4.5	5
94	Prognostic Predictions for Patients with Glioblastoma after Standard Treatment: Application of Contrast Leakage Information from DSC-MRI within Nonenhancing FLAIR High-Signal-Intensity Lesions. <i>American Journal of Neuroradiology</i> , 2019, 40, 2052-2058.	2.4	1
95	Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors. <i>BMC Cancer</i> , 2019, 19, 19.	2.6	66
96	A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2019, 24, 20.	3.7	29
97	A Phase I Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1953-1953.	1.4	15
98	Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study. <i>Blood</i> , 2019, 134, 1568-1568.	1.4	11
99	Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study. <i>Blood</i> , 2019, 134, 4081-4081.	1.4	10
100	First-in-human phase 1 study of the antibody-drug conjugate (ADC) SAR408701 in advanced solid tumors: Dose-expansion cohort of patients (pts) with non-squamous non-small cell lung cancer (NSQ) Tj ETQq0 0 ArgBT /Overlock 10 T		
101	Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 885-893.	1.7	9
102	Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1313-1323.	1.7	12
103	Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1116-1124.	1.7	6
104	The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 169-177.	3.0	3
105	Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. <i>Cancer Research and Treatment</i> , 2019, 51, 951-962.	3.0	48
106	Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1231-1240.	3.0	20
107	Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 894-901.	1.7	0
108	Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 736-744.	1.9	31

#	ARTICLE	IF	CITATIONS
109	Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With <i>BRAF</i> <sup>V600</sup> Mutation—Positive Metastatic Malignancy. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1067-1073.	2.0	11
110	Leakage correction improves prognosis prediction of dynamic susceptibility contrast perfusion MRI in primary central nervous system lymphoma. <i>Scientific Reports</i> , 2018, 8, 456.	3.3	7
111	Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. <i>American Journal of Hematology</i> , 2018, 93, 607-614.	4.1	75
112	CD21-independent Epstein-Barr virus entry into NK cells. <i>Cellular Immunology</i> , 2018, 327, 21-25.	3.0	12
113	Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma. <i>European Radiology</i> , 2018, 28, 4350-4361.	4.5	63
114	Differentiation of High-Grade from Low-Grade Astrocytoma: Improvement in Diagnostic Accuracy and Reliability of Pharmacokinetic Parameters from DCE MR Imaging by Using Arterial Input Functions Obtained from DSC MR Imaging. <i>Radiology</i> , 2018, 286, 981-991.	7.3	20
115	Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 459-470.	4.2	132
116	Loss of Pericytes in Radiation Necrosis after Glioblastoma Treatments. <i>Molecular Neurobiology</i> , 2018, 55, 4918-4926.	4.0	16
117	The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study. <i>Cancer Research and Treatment</i> , 2018, 50, 1186-1193.	3.0	17
118	ACTR-50. EFFECT OF CONCURRENT AND ADJUVANT TEMOZOLOMIDE ON SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED GRADE III GLIOMAS WITHOUT 1p/19q CO-DELETION: A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY (INTERIM RESULTS FROM THE KNOG-1101 STUDY). <i>Neuro-Oncology</i> , 2018, 20, vi23-vi23.	1.2	0
119	Comparison of Native <i>Escherichia coli</i> L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>Cancer Research and Treatment</i> , 2018, 50, 670-680.	3.0	9
120	Magnetic Nanowire Networks for Dual-Isolation and Detection of Tumor-Associated Circulating Biomarkers. <i>Theranostics</i> , 2018, 8, 505-517.	10.0	33
121	Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer. <i>Yonsei Medical Journal</i> , 2018, 59, 202.	2.2	7
122	Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. <i>ESMO Open</i> , 2018, 3, e000332.	4.5	55
123	Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study. <i>Blood</i> , 2018, 132, 1683-1683.	1.4	18
124	Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 108-108.	1.6	107
125	A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced <i>ALK/ROS1/NTRK+</i> cancers (TRIDENT-1).. <i>Journal of Clinical Oncology</i> , 2018, 36, 2513-2513.	1.6	15
126	Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7507-7507.	1.6	45



#	ARTICLE	IF	CITATIONS
127	Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma.. Journal of Clinical Oncology, 2018, 36, 7534-7534.	1.6	6
128	A phase II study of pembrolizumab and paclitaxel in refractory extensive disease small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, 8575-8575.	1.6	7
129	Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1.. Journal of Clinical Oncology, 2018, 36, 9017-9017.	1.6	10
130	Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS ONE, 2018, 13, e0189766.	2.5	46
131	The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer. Cancer Research and Treatment, 2018, 50, 720-728.	3.0	14
132	Multicenter Retrospective Analysis of Clinical Characteristics, Treatment Patterns, and Outcomes in Very Elderly Patients with Diffuse Large B-Cell Lymphoma: The Korean Cancer Study Group LY16-01. Cancer Research and Treatment, 2018, 50, 590-598.	3.0	7
133	A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies.. Journal of Clinical Oncology, 2018, 36, TPS2603-TPS2603.	1.6	1
134	Interim Analysis Results from an International, Multi-Centre, Non-Interventional Retrospective Study to Describe Treatment Pathways, Outcomes, and Resource Use in Patients with Classical Hodgkin Lymphoma: B-CD30+ Hodgkin Lymphoma International Multi-Centre Retrospective Study of Treatment Practices and Outcomes (B-HOLISTIC). Blood, 2018, 132, 2917-2917.	1.4	0
135	Clinicopathological categorization of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications. Leukemia and Lymphoma, 2017, 58, 53-63.	1.3	29
136	Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging. European Radiology, 2017, 27, 1176-1185.	4.5	27
137	Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experience. Leukemia and Lymphoma, 2017, 58, 2624-2632.	1.3	8
138	A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer. Targeted Oncology, 2017, 12, 463-474.	3.6	64
139	Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2017, 18, 874-886.	10.7	453
140	Preclinical development of a humanized neutralizing antibody targeting HGF. Experimental and Molecular Medicine, 2017, 49, e309-e309.	7.7	16
141	Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type. American Journal of Pathology, 2017, 187, 980-986.	3.8	44
142	Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Non-Small Cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy. Clinical Lung Cancer, 2017, 18, e169-e178.	2.6	20
143	Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study. European Radiology, 2017, 27, 3156-3166.	4.5	27
144	Role of radiation therapy in primary central nervous system lymphoma. Journal of Neuro-Oncology, 2017, 135, 629-638.	2.9	11

#	ARTICLE	IF	CITATIONS
145	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. <i>Nature Communications</i> , 2017, 8, 1050.	12.8	115
146	Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 891-902.	10.7	92
147	Recursive partitioning analysis for disease progression in adult intracranial ependymoma patients. <i>Journal of Clinical Neuroscience</i> , 2017, 46, 72-78.	1.5	3
148	Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 520-528.	1.1	21
149	Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. <i>Cancer Research and Treatment</i> , 2017, 49, 193-203.	3.0	26
150	Epstein-Barr Virus-Associated Vesiculopapular Eruption on the Face of a Patient with Natural Killer T Cell Lymphoma. <i>Annals of Dermatology</i> , 2017, 29, 618.	0.9	1
151	Korean Cancer Patients' Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate. <i>Cancer Research and Treatment</i> , 2017, 49, 1033-1043.	3.0	19
152	Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 3065-3074.	1.6	349
153	A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11078-11078.	1.6	26
154	Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2006-2006.	1.6	17
155	Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2069-2069.	1.6	12
156	Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3057-3057.	1.6	24
157	Updated survival of patients (pts) with previously treated BRAF V600E mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BR113928 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9075-9075.	1.6	37
158	Combined use of susceptibility weighted magnetic resonance imaging sequences and dynamic susceptibility contrast perfusion weighted imaging to improve the accuracy of the differential diagnosis of recurrence and radionecrosis in high-grade glioma patients. <i>Oncotarget</i> , 2017, 8, 20340-20353.	1.8	15
159	Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 97920-97927.	1.8	69
160	KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 514-522.	1.7	21
161	Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort. <i>Cancer Research and Treatment</i> , 2017, 49, 44-53.	3.0	27
162	Underexpression of HOXA11 Is Associated with Treatment Resistance and Poor Prognosis in Glioblastoma. <i>Cancer Research and Treatment</i> , 2017, 49, 387-398.	3.0	41

#	ARTICLE	IF	CITATIONS
163	Diffuse large B-cell lymphoma in very elderly patients older than 80 years: A multicenter retrospective analysis of clinical characteristics, treatment patterns, and outcomeâ€”KCSG LY16-01.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19031-e19031.	1.6	0
164	The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. <i>Cancer Research and Treatment</i> , 2016, 48, 907-916.	3.0	44
165	Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 570-578.	1.7	38
166	MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system. <i>BMC Cancer</i> , 2016, 16, 363.	2.6	37
167	MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction. <i>PLoS ONE</i> , 2016, 11, e0166096.	2.5	9
168	Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. <i>Histopathology</i> , 2016, 68, 1079-1089.	2.9	135
169	Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer. <i>Cancer Biomarkers</i> , 2016, 16, 425-433.	1.7	18
170	Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations. <i>Clinical Lung Cancer</i> , 2016, 17, 245-252.e1.	2.6	20
171	EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1 $\alpha$ and STAT3. <i>Oncolmmunology</i> , 2016, 5, e1108514.	4.6	124
172	Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2016, 17, 642-650.	10.7	352
173	Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 581-590.	2.8	71
174	The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2016, 34, 145-150.	1.5	1
175	Application of diffusion-weighted imaging and dynamic susceptibility contrast perfusion-weighted imaging for ganglioglioma in adults: Comparison study with oligodendroglioma. <i>Journal of Neuroradiology</i> , 2016, 43, 331-338.	1.1	10
176	Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience. <i>Head and Neck</i> , 2016, 38, 277-284.	2.0	14
177	Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. <i>Lancet Oncology, The</i> , 2016, 17, 984-993.	10.7	689
178	Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study. <i>BMC Cancer</i> , 2016, 16, 116.	2.6	31
179	Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era. <i>Cancer Research and Treatment</i> , 2016, 48, 304-311.	3.0	9
180	Phase I Study of Random Healthy Donorâ€”Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors. <i>Cancer Immunology Research</i> , 2016, 4, 215-224.	3.4	128

#	ARTICLE	IF	CITATIONS
181	Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 263-270.e2.	2.6	107
182	Predictors of survival for patients with cancer after cryptogenic stroke. <i>Journal of Neuro-Oncology</i> , 2016, 128, 277-284.	2.9	30
183	Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1387-1396.	4.1	25
184	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. <i>Clinical Cancer Research</i> , 2016, 22, 2261-2270.	7.0	217
185	Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. <i>BMC Cancer</i> , 2016, 16, 170.	2.6	30
186	Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 873-883.	2.5	17
187	An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. <i>Leukemia and Lymphoma</i> , 2016, 57, 1956-1960.	1.3	15
188	Injury-Mediated Vascular Regeneration Requires Endothelial ER71/ETV2. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 86-96.	2.4	54
189	Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study. <i>Blood</i> , 2016, 128, 4194-4194.	1.4	1
190	An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E mutant advanced non-small cell lung cancer (NSCLC); Tj ETQq0 0 0 rgBT /Overlock \$0 Tf 50 37		
191	Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9003-9003.	1.6	21
192	A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9013-9013.	1.6	16
193	PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 15901-15914.	1.8	125
194	Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 8389.	3.3	22
195	Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 1140-1149.	1.7	26
196	Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients. <i>Cancer Research and Treatment</i> , 2016, 48, 88-97.	3.0	19
197	Poor prognostic factors in human papilloma virus-positive head and neck cancer: Who should not be candidate of de-escalated treatment?. <i>Journal of Clinical Oncology</i> , 2016, 34, 6078-6078.	1.6	0
198	Ipilimumab real-world efficacy and safety in Asian melanoma patients from the Korean Named-Patient Program cohort.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21002-e21002.	1.6	0

#	ARTICLE	IF	CITATIONS
199	Korean Cancer Patients's Awareness of Clinical Trials: Perceptions on the benefit and willingness to participate.. Journal of Clinical Oncology, 2016, 34, 10067-10067.	1.6	0
200	Diagnosis of Secondary Peripheral Neurolymphomatosis: A Multi-Center Experience. Blood, 2016, 128, 4222-4222.	1.4	0
201	Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. Korean Journal of Internal Medicine, 2016, , .	1.7	0
202	Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma. Blood, 2015, 126, 1257-1258.	1.4	40
203	Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring <i>KIT</i> Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). Oncologist, 2015, 20, 1312-1319.	3.7	70
204	Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute. Cancer Research and Treatment, 2015, 47, 555-563.	3.0	49
205	Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. PLoS ONE, 2015, 10, e0133371.	2.5	7
206	Prediction of Response to Concurrent Chemoradiotherapy with Temozolomide in Glioblastoma: Application of Immediate Post-Operative Dynamic Susceptibility Contrast and Diffusion-Weighted MR Imaging. Korean Journal of Radiology, 2015, 16, 1341.	3.4	16
207	The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell Carcinoma. Journal of Urology, 2015, 194, 1112-1119.	0.4	19
208	MET amplification, protein expression, and mutations in pulmonary adenocarcinoma. Lung Cancer, 2015, 90, 381-387.	2.0	44
209	Mechanisms of Acquired Resistance to AZD9291. Journal of Thoracic Oncology, 2015, 10, 1736-1744.	1.1	202
210	Molecular Changes Associated with Acquired Resistance to Crizotinib in <i>ROS1</i> -Rearranged Non-Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 2379-2387.	7.0	116
211	Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL). Annals of Hematology, 2015, 94, 437-444.	1.8	32
212	Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. Journal of Neuro-Oncology, 2015, 121, 141-150.	2.9	92
213	Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. Modern Pathology, 2015, 28, 1154-1166.	5.5	143
214	Additional Survival Benefit of Involved-Lesion Radiation Therapy After R-CHOP Chemotherapy in Limited Stage Diffuse Large B-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2015, 92, 91-98.	0.8	22
215	Early cognitive function tests predict early progression in glioblastoma. Neuro-Oncology Practice, 2015, 2, 137-143.	1.6	14
216	A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. Oncologist, 2015, 20, 1119-1120.	3.7	20

#	ARTICLE	IF	CITATIONS
217	Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging. <i>Neuroradiology</i> , 2015, 57, 1111-1120.	2.2	9
218	Prefmab: Final Analysis of Patient Preference for Subcutaneous Versus Intravenous Rituximab in Previously Untreated CD20+ Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. <i>Blood</i> , 2015, 126, 3972-3972.	1.4	2
219	Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4554-4554.	1.6	5
220	Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8006-8006.	1.6	26
221	MR Imaging Evaluation of Intracerebral Hemorrhages and T2 Hyperintense White Matter Lesions Appearing after Radiation Therapy in Adult Patients with Primary Brain Tumors. <i>PLoS ONE</i> , 2015, 10, e0136795.	2.5	9
222	MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 15035-15049.	1.8	94
223	Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 891-898.	1.7	10
224	The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 182-188.	3.0	3
225	Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 670-675.	3.0	32
226	Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations. <i>Cancer Research and Treatment</i> , 2015, 47, 630-637.	3.0	21
227	Predictive and prognostic values of post chemoradiotherapy PET/CT and the effect of salvage surgery on survival in head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6052-6052.	1.6	0
228	In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. <i>Anticancer Research</i> , 2015, 35, 175-82.	1.1	29
229	Prognosis Prediction of Measurable Enhancing Lesion after Completion of Standard Concomitant Chemoradiotherapy and Adjuvant Temozolomide in Glioblastoma Patients: Application of Dynamic Susceptibility Contrast Perfusion and Diffusion-Weighted Imaging. <i>PLoS ONE</i> , 2014, 9, e113587.	2.5	15
230	Toxicity Profile of Temozolomide in the Treatment of 300 Malignant Glioma Patients in Korea. <i>Journal of Korean Medical Science</i> , 2014, 29, 980.	2.5	67
231	Anti-cancer activity of gemcitabine against natural killer cell leukemia/lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 940-943.	1.3	9
232	Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: Integrating with lung specific GPA score. <i>Lung Cancer</i> , 2014, 86, 363-368.	2.0	17
233	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non-Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1430.	7.4	136
234	A Phase II Study of Ifosfamide, Methotrexate, Etoposide, and Prednisolone for Previously Untreated Stage I/II Extranodal Natural Killer/Cell Lymphoma, Nasal Type: A Multicenter Trial of the Korean Cancer Study Group. <i>Oncologist</i> , 2014, 19, 1129-1130.	3.7	16

#	ARTICLE	IF	CITATIONS
235	Clinical Significance of Downstaging in Patients With Limited-Disease Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, e1-e6.	2.6	1
236	Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 2765-2772.	1.6	355
237	The presence of extrathoracic metastasis is more prognostic of survival than Masaoka stage (IVa/IVb) in metastatic thymic epithelial tumor: A retrospective cohort study. <i>Lung Cancer</i> , 2014, 85, 320-325.	2.0	6
238	Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 40.	1.7	31
239	Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Cancer Research and Treatment</i> , 2014, 46, 323-330.	3.0	21
240	Differentiation of True Recurrence from Delayed Radiation Therapy-related Changes in Primary Brain Tumors Using Diffusion-weighted Imaging, Dynamic Susceptibility Contrast Perfusion Imaging, and Susceptibility-weighted Imaging. <i>Journal of the Korean Society of Magnetic Resonance in Medicine</i> , 2014, 18, 120.	0.1	0
241	Cancer care near the end of life (EOL) in the era of molecular-targeted agents: Changes of trend during 10 years at single institution.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9543-9543.	1.6	0
242	Effect of induction chemotherapy (IC) on survival in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) treated with chemoradiotherapy: Single center experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, e17032-e17032.	1.6	0
243	Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. <i>Cancer</i> , 2013, 119, 1195-1202.	4.1	136
244	Surrogate decision-making in Korean patients with advanced cancer: a longitudinal study. <i>Supportive Care in Cancer</i> , 2013, 21, 183-190.	2.2	38
245	Phase I study (A8471004) in Asian patients of PF-03446962, a fully human mab against ALK-1 receptor involved in tumor angiogenesis: Safety, pharmacokinetics (PK), and pharmacodynamics (PD).. <i>Journal of Clinical Oncology</i> , 2013, 31, 11031-11031.	1.6	1
246	Phase I study to evaluate the safety and to assess the food effect of HM781-36B, a novel pan-HER inhibitor continuously given in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2565-2565.	1.6	1
247	Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4504-4504.	1.6	45
248	Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2013, 45, 325-333.	3.0	49
249	A phase II trial of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) for previously untreated stage I, II extranodal natural killer/T-cell lymphoma, nasal type (NTCL): A multicenter study of the Korean Cancer Study Group.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8521-8521.	1.6	0
250	Post-bevacizumab treatment and clinical outcomes in recurrent malignant glioma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2098-2098.	1.6	0
251	Predictive value of ribonucleotide reductase regulatory subunit M1 (RRM1) and excision cross-complementing-1 (ERCC1) in advanced urothelial carcinoma (UC) treated with first-line gemcitabine (G) and platinum (P)-based chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2013, 31, e15614-e15614.	1.6	0
252	The incidence, risk factors and prognostic implications of venous thromboembolism in Asian patients with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1590-1590.	1.6	0

#	ARTICLE	IF	CITATIONS
253	Clinical significance of downstaging in patients treated with chemoradiotherapy for limited-disease small cell lung cancer.. Journal of Clinical Oncology, 2013, 31, e18555-e18555.	1.6	0
254	A phase I study of HM781-36B, a novel pan-HER inhibitor, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, 3076-3076.	1.6	6
255	Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, 7566-7566.	1.6	1
256	Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.. Journal of Clinical Oncology, 2012, 30, 2041-2041.	1.6	0
257	Phase II trial of RAD001 in renal cell carcinoma patients with non-clear cell histology.. Journal of Clinical Oncology, 2012, 30, 4544-4544.	1.6	0
258	Response of chemoradiation therapy after induction chemotherapy failure in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).. Journal of Clinical Oncology, 2012, 30, 5552-5552.	1.6	0
259	First-line therapy with doxycycline in ocular adnexal mucosa-associated lymphoid tissue lymphoma: A retrospective analysis of clinical predictors. Cancer Science, 2010, 101, 1199-1203.	3.9	48
260	Extranodal NK/T-cell lymphoma, nasal type: New staging system and treatment strategies. Cancer Science, 2009, 100, 2242-2248.	3.9	68
261	Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIIE extranodal NK/T-cell lymphoma, nasal type. Blood, 2005, 106, 3785-3790.	1.4	165